---
title: "Eli Lilly's fourth-quarter revenue was USD 19.29 billion, a year-on-year increase of 43%. The expected full-year revenue is between USD 80 billion and USD 83 billion, with market expectations at USD 77.71 billion"
description: "Eli Lilly's fourth-quarter revenue was USD 19.29 billion, a year-on-year increase of 43%. The full-year revenue is expected to be between USD 80 billion and USD 83 billion, with market expectations at"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274805260.md"
published_at: "2026-02-04T11:47:20.000Z"
---

# Eli Lilly's fourth-quarter revenue was USD 19.29 billion, a year-on-year increase of 43%. The expected full-year revenue is between USD 80 billion and USD 83 billion, with market expectations at USD 77.71 billion

> Eli Lilly's fourth-quarter revenue was USD 19.29 billion, a year-on-year increase of 43%. The full-year revenue is expected to be between USD 80 billion and USD 83 billion, with market expectations at USD 77.71 billion

Eli Lilly's fourth-quarter revenue was USD 19.29 billion, a year-on-year increase of 43%. The expected full-year revenue is between USD 80 billion and USD 83 billion, while the market expectation is USD 77.71 billion.

Risk Warning and Disclaimer

The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the individual user's specific investment goals, financial situation, or needs. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at one's own risk

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 礼来升级 Zepbound 巩固优势、一支用整月！诺和诺德新药临床失利股价暴跌 | 礼来周一推出 Zepbound 多剂量 KwikPen 注射装置，患者仅需一支笔即可完成一个月四次给药，最低月价 299 美元，并已获 FDA 批准扩展标签。受此消息提振，礼来股价盘中涨超 5%。与此同时，竞争对手诺和诺德的下一代减肥药 C | [Link](https://longbridge.com/en/news/276630276.md) |
| 诺和诺德明年大幅下调减肥神药在美售价，降幅最高 50% | 诺和诺德宣布将司美格鲁肽系列药物美国月标价统一降至 675 美元，降幅最高 50%，明年 1 月生效，旨在应对礼来竞争与市场压力。消息公布后美股盘前跌 3%，本周因新药数据不佳已累跌 19%。降价主要惠及高免赔额计划参保人，与 Medica | [Link](https://longbridge.com/en/news/276745048.md) |
| 阿克迈技术｜10-K：2025 财年营收 42.08 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276486503.md) |
| 美银：应对地缘需 “交易石油、持有黄金”，美股摆脱低迷需 “两大外部冲击” | Hartnett 的最新报告揭示了当前美股最尴尬的处境：基本面虽好但拥挤不堪，资金面开始松动且流向海外。面对地缘政治的迷雾与高位震荡的美股，投资者应当短期 “交易石油”，中期 “持有黄金”；而美股若想打破当前 “极度看涨却又滞涨” 的僵局， | [Link](https://longbridge.com/en/news/276558568.md) |
| “彻底失望”！德银首次下调诺和诺德评级 | 德意志银行首次下调诺和诺德股票评级至 “持有”，因其减肥药 CagriSema 在临床试验中表现不佳，导致市场抛售，股价暴跌 16%。摩根大通也下调评级并大幅削减销售预期，华尔街对该股的看涨比例降至数年最低，显示出对诺和诺德中期前景的悲观情 | [Link](https://longbridge.com/en/news/276727300.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.